Business News (Dec. 12) – PAC-1, a drug originally developed by scientists at the University of Illinois at Urbana-Champaign, triggers programmed cell death in cancer cells. Most notably, it managed to halt tumor growth in five participants suffering from neuroendocrine cancer. Impressively, two of these patients saw a reduction in tumor size. The drug also demonstrated therapeutic activity against sarcoma.
PAC-1 Anti-Cancer Agent Shines in Human Trials
